Chemerin: At the crossroads of inflammation and obesity

Trends in Endocrinology and Metabolism

Volumn 21, Issue 11, 2010, Pages 660-667

  Ernst, Matthew C ^a   Sinal, Christopher J ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; CHEMERIN; CHOLESTEROL; G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 30; G PROTEIN COUPLED RECEPTOR CHEMOKINE LIKE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ATHEROSCLEROTIC PLAQUE; BODY MASS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CHEMOTAXIS; CHOLESTEROL BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LYMPHOCYTIC INFILTRATION; MACROPHAGE; METABOLIC SYNDROME X; METABOLISM; MYELOID DENDRITIC CELL; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; CHEMOKINES; GLUCOSE; HOMEOSTASIS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; OBESITY; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 78049314118     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.08.001     Document Type: Review

References (79)

1. Nagpal S., et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J. Invest. Dermatol. 1997, 109:91-95.
2. Wittamer V., et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 2003, 198:977-985.
3. Wittamer V., et al. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J. Immunol. 2005, 175:487-493.
4. Zabel B.A., et al. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J. Immunol. 2005, 174:244-251.
5. Vermi W., et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J. Exp. Med. 2005, 201:509-515.
6. Goralski K.B., et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 2007, 282:28175-28188.
7. Bozaoglu K., et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007, 148:4687-4694.
8. Meder W., et al. Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23. FEBS Lett. 2003, 555:495-499.
9. Zabel B.A., et al. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J. Exp. Med. 2008, 205:2207-2220.
10. Zabel B.A., et al. Chemokine-like receptor 1 expression by macrophages in vivo: regulation by TGF-beta and TLR ligands. Exp. Hematol. 2006, 34:1106-1114.
11. Zabel B.A., et al. Chemoattractants, extracellular proteases, and the integrated host defense response. Exp. Hematol. 2006, 34:1021-1032.
12. Zabel B.A., et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J. Biol. Chem. 2005, 280:34661-34666.
13. Du X.Y., et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J. Biol. Chem. 2009, 284:751-758.
14. Guillabert A., et al. Role of neutrophil proteinase 3 and mast cell chymase in chemerin proteolytic regulation. J. Leukoc. Biol. 2008, 84:1530-1538.
15. John H., et al. Quantification of angiotensin-converting-enzyme-mediated degradation of human chemerin 145-154 in plasma by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Anal. Biochem. 2007, 362:117-125.
16. Wittamer V., et al. The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J. Biol. Chem. 2004, 279:9956-9962.
17. Cash J.L., et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 2008, 205:767-775.
18. Shimamura K., et al. Identification of a stable chemerin analog with potent activity toward ChemR23. Peptides 2009, 30:1529-1538.
19. Cash J.L., et al. Chemerin peptides promote phagocytosis in a ChemR23- and Syk-dependent manner. J. Immunol. 2010, 184:5315-5324.
20. Parolini S., et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 2007, 109:3625-3632.
21. Weigert J., et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin. Endocrinol. (Oxf.) 2010, 72:342-348.
22. Lehrke M., et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur. J. Endocrinol. 2009, 161:339-344.
23. Bos J.D., et al. Psoriasis: dysregulation of innate immunity. Br. J. Dermatol. 2005, 152:1098-1107.
24. Nickoloff B.J. Skin innate immune system in psoriasis: friend or foe?. J. Clin. Invest 1999, 104:1161-1164.
25. Ottaviani C., et al. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur. J. Immunol. 2006, 36:118-128.
26. Albanesi C., et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J. Exp. Med. 2009, 206:249-258.
27. Albanesi C., et al. Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity 2010, 43:215-219.
28. Skrzeczynska-Moncznik J., et al. Potential role of chemerin in recruitment of plasmacytoid dendritic cells to diseased skin. Biochem. Biophys. Res. Commun. 2009, 380:323-327.
29. Moretta A., et al. NK cells at the interface between innate and adaptive immunity. Cell Death Differ. 2008, 15:226-233.
30. Colonna M., et al. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
31. Gerosa F., et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J. Immunol. 2005, 174:727-734.
32. Graham K.L., et al. Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease. J. Immunol. 2009, 183:6717-6723.
33. Luangsay S., et al. Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J. Immunol. 2009, 183:6489-6499.
34. Caspar-Bauguil S., et al. Adipose tissue lymphocytes: types and roles. J. Physiol. Biochem. 2009, 65:423-436.
35. Weisberg S.P., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
36. Anderson E.K., et al. Adipose tissue recruitment of leukocytes. Curr. Opin. Lipidol. 2010, 21:172-177.
37. Kern P.A., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E745-751.
38. Cottam D.R., et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes. Surg. 2004, 14:589-600.
39. Trayhurn P., Wood I.S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 2005, 33:1078-1081.
40. Cinti S., et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46:2347-2355.
41. Strissel K.J., et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007, 56:2910-2918.
42. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000, 11:327-332.
43. Fruhbeck G., et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E827-847.
44. Goralski K.B., Sinal C.J. Type 2 diabetes and cardiovascular disease: getting to the fat of the matter. Can. J. Physiol. Pharmacol. 2007, 85:113-132.
45. Karlsson C., et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab 1998, 83:3925-3929.
46. Lopez X., et al. Human insulin analog--induced lipoatrophy. Diabetes Care 2008, 31:442-444.
47. Taleb S., et al. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J. 2005, 19:1540-1542.
48. Galvez-Prieto B., et al. Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J. Endocrinol. 2008, 197:55-64.
49. Engeli S., et al. Co-expression of renin-angiotensin system genes in human adipose tissue. J. Hypertens. 1999, 17:555-560.
50. Bottcher A., et al. Angiotensin-converting enzyme signalling in human preadipocytes and adipocytes. Cent. Eur. J. Biol. 2006, 1:203-220.
51. Muruganandan S., et al. Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J. Bone Miner. Res. 2010, 25:222-234.
52. Brakenhielm E., et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ. Res. 2004, 94:1579-1588.
53. Neels J.G., et al. Angiogenesis in an in vivo model of adipose tissue development. FASEB J. 2004, 18:983-985.
54. Rupnick M.A., et al. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10730-10735.
55. Kaur J., et al. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem. Biophys. Res. Commun. 2010, 391:1762-1768.
56. Bozaoglu K., et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J. Clin. Endocrinol. Metab. 2010, 95:2476-2485.
57. Bozaoglu K., et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican American Population. J. Clin. Endocrinol. Metab. 2009, 94:3085-3088.
58. Stejskal D., et al. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population--a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008, 152:217-221.
59. Mussig K., et al. RARRES2, encoding the novel adipokine chemerin, is a genetic determinant of disproportionate regional body fat distribution: a comparative magnetic resonance imaging study. Metabolism 2009, 58:519-524.
60. Hamdy O., et al. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr. Diabetes Rev. 2006, 2:367-373.
61. Ress C., et al. Effect of bariatric surgery on circulating chemerin levels. Eur. J. Clin. Invest. 2010, 40:277-280.
62. Sell H., et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 2010, 95:2892-2896.
63. Tan B.K., et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009, 58:1971-1977.
64. Sell H., et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009, 58:2731-2740.
65. Ernst M.C., et al. Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology 2010, 151:1998-2007.
66. Parlee S.D., et al. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-α. Endocrinology 2010, 151:2590-2602.
67. Spiroglou S.G., et al. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J. Atheroscler. Thromb. 2010, 17:115-130.
68. Kralisch S., et al. Interleukin-1beta induces the novel adipokine chemerin in adipocytes in vitro. Regul. Pept. 2009, 154:102-106.
69. Roh S.G., et al. Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem. Biophys. Res. Commun. 2007, 362:1013-1018.
70. Vernochet C., et al. Mechanisms regulating repression of haptoglobin production by peroxisome proliferator-activated receptor-gamma ligands in adipocytes. Endocrinology 2010, 151:586-594.
71. Vernochet C., et al. C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol. Cell. Biol. 2009, 29:4714-4728.
72. Muoio D.M., Newgard C.B. Obesity-related derangements in metabolic regulation. Annu. Rev. Biochem. 2006, 75:367-401.
73. James P.T., et al. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur. J. Cardiovasc. Prev. Rehabil. 2004, 11:3-8.
74. Poirier P., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler. Thromb. Vasc. Biol. 2006, 26:968-976.
75. Fain J.N., et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273-2282.
76. Dandona P., et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 1998, 83:2907-2910.
77. Folsom A.R., et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler. Thromb 1993, 13:162-169.
78. Itoh K., et al. Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens. Res. 2002, 25:881-886.
79. Takahashi M., et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett. 2008, 582:573-578.